Brief: Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18
Aug 06 (Reuters) - Acadia Pharmaceuticals Q2 product sales USD 241.963 million vs. IBES estimate USD 235.4 million. * Q2 pretax profit USD 37.182 million vs. IBES estimate USD 32.1 million * Q2 net income USD 33.389 million vs. IBES estimate USD 31.1 million * Q2 operating expenses USD 211.526 million
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry